Compare Aurora Cannabis Inc (ACB) vs Global X Cloud Computing ETF (CLOU) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

CLOU, the Global X Cloud Computing ETF, trades at $27.28, up 3.88% in the past 24 hours. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. Recent news highlights long-term growth prospects driven by cloud computing expansion beyond AI, with top holdings like Snowflake and Datadog showing resilience.

The outlook for CLOU remains positive due to sector tailwinds and diversified cloud exposure, but risks include market volatility and competition from European tech initiatives. Investors should weigh growth potential against valuation concerns in the tech sector.